Name,Vaccine Type,Details,Primary Developers,Country of Origin,Authorization/Approval
ARCoV,mRNA-based vaccine,"Walvax Biotechnology Co., Ltd.; Abogen Biosciences Co. Ltd.; Yuxi Walvax Biotechnology Co., Ltd.",Phase 3,Xiangfen CDC,
NVX-CoV2373,Nanoparticle vaccine,Novavax,Phase 3,Novavax,
ZyCoV-D,DNA vaccine (plasmid),Zydus Cadila,Phase 3,Zydus Cadila,
Abdala (CIGB 66),Protein subunit vaccine,Center for Genetic Engineering and Biotechnology,Phase 3,Center for Genetic Engineering and Biotechnology,
Unnamed vaccine candidate,Plant-based adjuvant vaccine,Medicago; GSK; Dynavax,Phase 3,Medicago,
VLA2001,Inactivated vaccine,Valneva;UK National Institute for Health Research,Phase 3,Multiple NIHR testing sites,
No name announced,Adjuvanted protein subunit vaccine,"Biological E, Baylor College of Medicine, Dynavax, CEPI",Phase 3,Various,
No name announced,Recombinant protein vaccine,Sanofi; GlaxoSmithKline,Phase 3,Various,
Nanocovax,Recombinant vaccine (Spike protein),Nanogen Biopharmaceutical,Phase 3,Military Medical Academy (Vietnam),
CVnCoV,mRNA-based vaccine,CureVac; GSK,Phase 2b/3,CureVac,
Bacillus Calmette-Guerin (BCG) vaccine,Live-attenuated vaccine,University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital,Phase 2/3,University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital,
INO-4800,DNA vaccine (plasmid),Inovio Pharmaceuticals; Advaccine,Phase 2/3,"Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia",
No name announced,Adenovirus-based vaccine,ImmunityBio; NantKwest,Phase 2/3,,
UB-612,Multitope peptide-based vaccine,Vaxxinity,Phase 2/3,United Biomedical Inc. (UBI),
GRAd-COV2,Adenovirus-based vaccine,ReiThera; Leukocare; Univercells,Phase 2/3,Lazzaro Spallanzani National Institute for Infectious Diseases,
SCB-2019,Protein subunit vaccine,"GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI",Phase 2/3,Linear Clinical Research (Australia),
V-01,Recombinant protein vaccine,"Guangdong Provincial Center for Disease Control and Prevention; Gaozhou Municipal Center for Disease Control and Prevention; Zhuhai Livzonumab Biotechnology Co., Ltd.",Phase 2,Livzon Mabpharm Inc.,
Razi Cov Pars,Recombinant vaccine (Spike protein),Razi Vaccine and Serum Research Institute,Phase 2,Tehran Rasoul Akram Hospital,
Unnamed vaccine candidate,Recombinant vaccine (CHO cells),"Jiangsu Province Centers for Disease Control and Prevention; Academy of Military Medical Sciences; Zhongyianke Biotech Co, Ltd.; Liaoningmaokangyuan Biotech Co, Ltd",Phase 2,Jiangsu Province Centers for Disease Control and Prevention,
COVAX-19,Monovalent recombinant protein vaccine,Vaxine Pty Ltd.; CinnaGen,Phase 2,Royal Adelaide Hospital,
BNT162,mRNA-based vaccine,"Pfizer, BioNTech",Phase 1/2/3,"Multiple study sites in Europe, North America and China",
Soberana 1 and 2,Monovalent/conjugate vaccine,Finlay Institute of Vaccines,Phase 1/2/3,Finlay Institute of Vaccines,
AdCLD-CoV19,Adenovirus-based vaccine,Cellid; LG Chem,Phase 1/2a,Korea University Guro Hospital,
QazCoVac-P,Protein subunit vaccine,Research Institute for Biological Safety Problems,Phase 1/2,Research Institute for Biological Safety Problems,
DelNS1-nCoV-RBD LAIV,Intranasal vaccine,Xiamen University; University of Hong Kong; Beijing Wantai Biological Pharmacy; CEPI,Phase 1/2,HKU Phase 1 Clinical Trials Centre,
IVX-411,Virus-like particle vaccine,"Icosavax, Inc.; Bill & Melinda Gates Foundation; Amgen; Seqirus",Phase 1/2,,
KD-414,Inactivated vaccine,KM Biologics; Japan Agency for Medical Research and Development,Phase 1/2,,
Unnamed vaccine candidate,Recombinant vaccine (CHO cells),"National Vaccine and Serum Institute; Lanzhou Institute of Biological Products Co., Ltd; Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.; Zhengzhou University",Phase 1/2,Ning ling Center for Disease Control and Prevention,
VBI-2902a,Virus-like particle vaccine (enveloped),VBI Vaccines Inc.,Phase 1/2,Various,
COVID-eVax,DNA vaccine (plasmid),Takis; Rottapharm Biotech,Phase 1/2,Various sites in Italy,
S-268019,Recombinant protein vaccine,"Shionogi & Co., Ltd; Japan Agency for Medical Research and Development",Phase 1/2,,
GLS-5310,DNA vaccine,"GeneOne Life Science, Inc.",Phase 1/2,Korea University Guro Hospital,
Covigenix VAX-001,DNA vaccine (plasmid),"Entos Pharmaceuticals Inc.; Aegis Life, Inc.; Canadian Institutes of Health Research (CIHR)",Phase 1/2,"Canadian Centre for Vaccinology, Dalhousie University",
Unnamed vaccine candidate,Synthetic minigene vaccine,Shenzhen Geno-Immune Medical Institute; Shenzhen Third People's Hospital; Shenzhen Second People's Hospital,Phase 1/2,Shenzhen Geno-immune Medical Institute,
EXG-5003,Intradermal vaccine candidate,"Fujita Health University; Elixirgen Therapeutics, Inc.",Phase 1/2,Fujita Health University Hospital,
AKS-452,Protein subunit vaccine,University Medical Center Groningen; Akston Biosciences,Phase 1/2,University Medical Center Groningen,
DS-5670a,mRNA-based vaccine,"Daiichi Sankyo Co., Ltd.",Phase 1/2,SouseikaiHakata Clinic,
ABNCoV2,cVLP-based vaccine,ExpreS2ion Biotech; Bavarian Nordic A/S,Phase 1/2,,
EuCorVac-19,nanoparticle vaccine,EuBiologics,Phase 1/2,Eunpyeong St. Mary’s Hospital,
Mambisa (CIGB 669),Protein subunit vaccine,Center for Genetic Engineering and Biotechnology,Phase 1/2,Center for Genetic Engineering and Biotechnology,
IIBR-100,Recombinant vesicular stomatitis virus (rVSV) vaccine,Israel Institute for Biological Research,Phase 1/2,Hadassah Medical Center; Sheba Medical Center Hospital,
No name announced,SF9 cell vaccine candidate,"West China Hospital, Sichuan University",Phase 1/2,"West China Hospital, Sichuan University",
AG0301-COVID19,DNA vaccine,"AnGes, Inc.",Phase 1/2,"AnGes, Inc.; Japan Agency for Medical Research and Development",
GX-19N,DNA vaccine,Genexine,Phase 1/2,,
ARCT-021 (LUNAR-COV19),Self-replicating RNA vaccine,Arcturus Therapeutics and Duke-NUS Medical School,Phase 1/2,"Duke-NUS Medical School, Singapore",
HDT-301 (HGCO19),RNA vaccine,University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp; Gennova Biopharmaceuticals,Phase 1/2,,
MRT5500,mRNA-based vaccine,"Sanofi, Translate Bio",Phase 1/2,,
AV-COVID-19,Dendritic cell vaccine,"Aivita Biomedical, Inc.",Phase 1b/2,Rumah Sakit Umum Pusat Dr Kariadi,
Unnamed vaccine candidate,Recombinant Newcastle disease virus vectored vaccine,"Laboratorio Avi-Mex, S.A. de C.V.; National Council of Science and Technology, Mexico",Phase 1,Hospital Medica Sur,
Unnamed vaccine candidate,mRNA-based vaccine,Shanghai Municipal Science and Technology Commission; Stemirna Therapeutics,Phase 1,Shulan (Hangzhou) Hospital,
FAKHRAVAC (MIVAC),Inactivated vaccine,The Stem Cell Technology Research Center; Organization of Defensive Innovation and Research,Phase 1,Fakhra Clinical Trial Center,
Unnamed vaccine candidate,ChAdV68 serotype; self-amplifying mRNA vaccine,"Gritstone Oncology, Inc.; NIAID",Phase 1,Various,
NBP2001,Recombinant protein vaccine,"SK Bioscience Co., Ltd.",Phase 1,Seoul National University Bundang Hospital; Seoul National University Hospital,
Unnamed vaccine candidate,Artificial antigen presenting cell (aAPC) vaccine,Shenzhen Geno-Immune Medical Institute; Shenzhen Third People's Hospital; Shenzhen Second People's Hospital,Phase 1,Shenzhen Geno-immune Medical Institute,
BBV154,Intranasal vaccine,Bharat Biotech,Phase 1,Various,
Unnamed vaccine candidate,Inactivated vaccine,The Scientific and Technological Research Council of Turkey; VETAL Inc.; MonitorCRO,Phase 1,Ankara City Hospital Phase I Drug Research Center,
Unnamed vaccine candidate,Inactivated vaccine,Kocak Farma,Phase 1,Yeditepe AR-GE ve Analiz Merkezi İyi Klinik Uygulamaları Merkezi (Center for GCP),
Unnamed vaccine candidate,Virus-like particle vaccine,The Scientific and Technological Research Council of Turkey; Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital; MonitorCRO; Nobel Pharmaceuticals,Phase 1,Dr. Abdurahman Yurtaslan Ankara Oncology Training and Research Hospital Phase I Clinical Study Center,
SpFN,Spike ferritin nanoparticle vaccine,US Army Medical Research and Development Command,Phase 1,Walter Reed Army Institute of Research,
KBP-201,Protein subunit vaccine,"Kentucky BioProcessing, Inc.",Phase 1,Velocity Clinical Research; PMG Research of Winston-Salem; ICON; DM Clinical Research,
MV-014-212,Intranasal vaccine,"Meissa Vaccines, Inc.",Phase 1,Johnson County Clin-Trials; Meridian Clinical Research,
PTX-COVID19-B,mRNA-based vaccine,Providence Therapeutics; Canadian government,Phase 1,,
COVI-VAC,Intranasal vaccine,Codagenix; Serum Institute of India,Phase 1,,
CORVax12,DNA vaccine (plasmid),OncoSec; Providence Cancer Institute,Phase 1,Providence Portland Medical Center,
MVA-SARS-2-S,Modified vaccinia virus ankara (MVA) vector vaccine candidate,Universitätsklinikum Hamburg-Eppendorf; German Center for Infection Research; Philipps University Marburg Medical Center; Ludwig-Maximilians - University of Munich,Phase 1,University Medical Center Hamburg-Eppendorf,
COH04S1,Modified vaccinia virus ankara (MVA) vector vaccine candidate,City of Hope Medical Center; National Cancer Institute,Phase 1,City of Hope Medical Center,
pVAC,Multi-peptide vaccine candidate,University Hospital Tuebingen,Phase 1,University Hospital Tuebingen,
AdimrSC-2f,Protein subunit vaccine,Adimmune,Phase 1,Adimmune,
bacTRL-Spike,Monovalent oral vaccine (bifidobacteria),Symvivo,Phase 1,Symvivo Corporation,
DelNS1-2019-nCoV-RBD-OPT1,Replicating viral vector,"Xiamen University, Beijing Wantai Biological Pharmacy",Phase 1,Jiangsu Provincial Centre For Disease Control and Prevention,
UQ-CSL V451,Protein subunit vaccine,CSL; The University of Queensland,Phase 1,,
VXA-CoV2-1,Recombinant vaccine (adenovirus type 5 vector),Vaxart,Phase 1,Vaxart,
AdCOVID,Intranasal vaccine,Altimmune; Summit Biosciences,Phase 1,University of Alabama at Birmingham,
COVAC-2,Protein subunit vaccine,University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre,Phase 1,University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre,
AAVCOVID,Gene-based vaccine,Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania,Pre-clinical,,
ChAd-SARS-CoV-2-S,Adenovirus-based vaccine,Washington University School of Medicine in St. Louis,Pre-clinical,Washington University School of Medicine in St. Louis,
HaloVax,Self-assembling vaccine,"Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.",Pre-clinical,MGH Vaccine and Immunotherapy Center,
LineaDNA,DNA vaccine,Takis Biotech,Pre-clinical,Takis Biotech,
No name announced,Ii-Key peptide COVID-19 vaccine,"Generex Biotechnology; Beijing Youfeng Biological Technology, Ltd",Pre-clinical,Generex,
No name announced,mRNA-based vaccine,Chulalongkorn University’s Center of Excellence in Vaccine Research and Development,Pre-clinical,,
No name announced,gp96-based vaccine,Heat Biologics,Pre-clinical,University of Miami Miller School of Medicine,
PittCoVacc,Recombinant protein subunit vaccine (delivered through microneedle array),UPMC/University of Pittsburgh School of Medicine,Pre-clinical,University of Pittsburgh,
T-COVIDTM,Intranasal vaccine,Altimmune,Pre-clinical,,
LNP-nCoVsaRNA,Self-amplifying RNA vaccine,Imperial College London,No longer being studied,Imperial College London,
V590,Recombinant vaccine (vesicular stomatitis virus),Merck; IAVI,No longer being studied,,
V591,Measles vector vaccine,University of Pittsburgh’s Center for Vaccine Research,No longer being studied,"University of Pittsburgh; Themis Biosciences; Institut Pasteur""",
